| Name | ethyl 2-[2-(4-chlorophenyl)-5-(furan-2-yl)-1,3-oxazol-4-yl]acetate |
|---|---|
| Synonyms |
ta 1801
TA-1801 |
| Description | TA-1801 is a hypolipidemic agent. |
|---|---|
| Related Catalog | |
| In Vitro | TA-1801 inhibits platelet aggregation in vitro[1]. |
| In Vivo | TA-1801 reduces serum cholesterol and triglyceride levels by 23% and 35%, respectively, at a dose of 0.05% in a diet in normal rats, and it is about 10 times more active in hereditary hyperlipidemic rats (THLR/1) than in normal rats[1]. |
| References |
| Density | 1.275g/cm3 |
|---|---|
| Boiling Point | 471ºC at 760 mmHg |
| Molecular Formula | C17H14ClNO4 |
| Molecular Weight | 331.75000 |
| Flash Point | 238.6ºC |
| Exact Mass | 331.06100 |
| PSA | 65.47000 |
| LogP | 4.36060 |
| Index of Refraction | 1.556 |
| Storage condition | 2-8℃ |
| Precursor 3 | |
|---|---|
| DownStream 0 | |